Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study
…, P Varlet, H Loiseau, S Lacomme… - … of Neuropathology & …, 2020 - academic.oup.com
The diagnosis of anaplastic meningioma (AM) (WHO grade III) is based on the presence of
a high mitotic index (MI) and/or overt anaplasia. Only few data exist about the reproducibility …
a high mitotic index (MI) and/or overt anaplasia. Only few data exist about the reproducibility …
[HTML][HTML] Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
…, E Wasielewski, L Wicquart, S Lacomme… - …, 2019 - thelancet.com
Background Malignant Pleural Mesothelioma (MPM) is an aggressive disease related to
asbestos exposure, with no effective therapeutic options. Methods We undertook unsupervised …
asbestos exposure, with no effective therapeutic options. Methods We undertook unsupervised …
Methyl (R217) HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma
…, L Brochin, A Luc, C Paris, S Lacomme… - Lung cancer, 2015 - Elsevier
Objectives In non small cell lung carcinoma (NSCLC), earlier studies supported a prognostic
value of intra-cytoplasmic HuR expression. HuR is a RNA binding protein previously shown …
value of intra-cytoplasmic HuR expression. HuR is a RNA binding protein previously shown …
[HTML][HTML] Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their
molecular characteristics. Through machine learning and multi-omics factor analysis, we …
molecular characteristics. Through machine learning and multi-omics factor analysis, we …
[HTML][HTML] Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
…, P Hofman, J Mouroux, C Cohen, S Lacomme… - Nature Genetics, 2023 - nature.com
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and
challenging clinical management. Through a large series of whole-genome sequencing data, …
challenging clinical management. Through a large series of whole-genome sequencing data, …
Ki‐67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1‐mutant and 1p/19q‐codeleted: a multicenter study from …
…, S Hergalant, E Lardenois, S Lacomme… - Brain …, 2020 - Wiley Online Library
Anaplastic oligodendroglioma (AO), IDH‐mutant and 1p/19q codeleted (IDHmut+/1p19qcodel),
is a high‐grade glioma with only limited prognostic markers. The primary objective of this …
is a high‐grade glioma with only limited prognostic markers. The primary objective of this …
BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis
G Gauchotte, C Philippe, S Lacomme, B Léotard… - Pathology, 2011 - Elsevier
Aims The aim of this study was to genotype a series of papillary thyroid carcinomas (PTCs)
and anaplastic thyroid carcinomas (ATCs) for BRAF mutation, and to evaluate p53 and SOX2 …
and anaplastic thyroid carcinomas (ATCs) for BRAF mutation, and to evaluate p53 and SOX2 …
DNA methylation associated with polycomb repression in retinoic acid receptor β silencing
…, C Champion, A Ceccaldi, S Lacomme… - The FASEB …, 2013 - Wiley Online Library
Retinoic acid receptor β 2 (RARβ2) is a tumor suppressor gene whose loss of expression is
recurrent in prostate cancers. Here we studied the epigenetic mechanisms leading to its …
recurrent in prostate cancers. Here we studied the epigenetic mechanisms leading to its …
Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells
…, F Bihain, C Nominé-Criqui, Y Goumon, S Lacomme… - Cancer Letters, 2022 - Elsevier
Increasingly common, neuroendocrine tumors (NETs) are regarded nowadays as
neoplasms potentially causing debilitating symptoms and life-threatening medical conditions. …
neoplasms potentially causing debilitating symptoms and life-threatening medical conditions. …
[HTML][HTML] Prospective multicenter validation of the detection of ALK rearrangements of circulating tumor cells for noninvasive longitudinal management of patients with …
…, C Clement-Duchene, JM Vignaud, S Lacomme… - Journal of Thoracic …, 2021 - Elsevier
Introduction Patients with advanced-stage NSCLC whose tumors harbor an ALK gene
rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of …
rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of …